Antigenics Inc.  (AGEN) Trade Now »     Rate AGEN  -  Discuss AGEN  -  Add to Watch List        

Investors of Antigenics Inc. (AGEN) expecting big news from Wednesday's shareholder meeting were mostly disappointed with the fact that the conference call was just a rehash of recent events and was not the stage for a significant announcement. However, those who were disappointed by the lack of significant news were most likely just day and swing traders potentially looking to make a quick buck. For the long term shareholder, CEO Garo Armen provided some encouraging updates.

After soaring from sixty cents to over three dollars per share in the timespan of a few days, Antigenics (AGEN) was trading for under two dollars during early training on Monday morning.

Drops such as this one tend to induce a fair amount of selling from 'weak hands', or those that knee-jerk their sell orders at the first sign of trouble, but this is a buying opportunity that the long term investor should not miss.

AGEN's Contrary Indicator
AGEN Stock Watch

Early last week Antigenics' (AGEN) stock dropped 13% on fairly heavy volume before rebounding in the days leading up to the American Society of Clinical Oncology ((ASCO)) annual meeting that took place in Orlando, Florida this past weekend.